We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 917

Federal Supreme Court passes stem cell case to ECJ
  • Cohausz & Florack
  • European Union, Germany
  • December 9 2009

On 12th November 2009 the Federal Supreme Court was due to consider the patentability of methods to generate cells from embryonic stem cells

German DPA fines drugstore chain 137,500 for illegal collection of health data
  • Hunton & Williams LLP
  • Germany
  • January 19 2010

On January 11, 2010, the data protection authority of the German federal state of Baden-Wurtemberg issued a press release stating that it had fined the Müller Group 137,500 for illegal retention of health-related data and failure to appoint a Data Protection Officer

Higher Administrative Court of North Rhine-Westphalia rules on liability of German parallel importer for violation of (local) distribution law by a pharmaceutical wholesaler in another EU Member State
  • Eversheds
  • European Union, Germany
  • May 6 2016

Parallel imports of medicines are, in principle, permitted within the EU. In particular, the price differences in different countries for medicines

Criteria for search engine AdWords advertising defined by Federal Supreme Court
  • Baker & McKenzie
  • Germany
  • March 17 2014

The questions of whether pharmaceutical companies in Germany are permitted to advertise OTC products through search engine AdWords advertising, and if

The Bolar exemption protection of API suppliers
  • Bird & Bird
  • European Union, Germany
  • May 18 2014

The CJEU has recently been asked by the German courts to consider whether the Bolar exemption extends to a third party manufacturer which supplies a

Infringement of second medical use claims in Germany
  • Taylor Wessing
  • Germany
  • July 30 2014

There has recently been debate about the infringement of second medical use claims, in particular with regard to cross label use and skinny labelling

It might take three to Bolar
  • De Brauw Blackstone Westbroek
  • Germany
  • February 10 2014

The Düsseldorf Court of Appeal recently challenged established opinion that a third-party's supply of ingredients to a generic pharmaceutical

International news: focus on compliance - winter 2014
  • McDermott Will & Emery
  • China, European Union, Germany, Global, USA
  • December 2 2014

As regulatory oversight of companiesfrom Sarbanes Oxley and the Dodd-Frank Act to the Foreign Corrupt Practices Act (FCPA) and the UK Bribery

  • SKW Schwarz Rechtsanwälte
  • Germany
  • February 13 2015

By law, a company can market a pharmaceutical product only once it has received marketing authorisation. Marketing authorisation can be obtained

Connected health: legal aspects of health apps in Germany
  • Taylor Wessing
  • Germany
  • April 20 2015

In the near future, your smartphone may act as a "portable GP": Analysing the data from a wireless sensor patch on your body to warn you about your